m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression

Gefitinib has been widely applied for the treatment of lung adenocarcinoma (LUAD). However, the long-term application of gefitinib usually leads to acquired drug resistance in tumour patients, resulting in clinical treatment failure. Small nucleolar host gene 17 (SNHG17) has been shown to play a reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Heng, Wang, Shao-Qiang, Wang, Li, Lin, Hang, Zhu, Jie-Bo, Chen, Ri, Li, Lin-Feng, Cheng, Yuan-Da, Duan, Chao-Jun, Zhang, Chun-Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334586/
https://www.ncbi.nlm.nih.gov/pubmed/35902569
http://dx.doi.org/10.1038/s41419-022-05050-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334586/
https://www.ncbi.nlm.nih.gov/pubmed/35902569
http://dx.doi.org/10.1038/s41419-022-05050-x

Ejemplares similares